Gilead Sciences is a Foster City–based biopharma specializing in antiviral medicines and therapies for HIV, hepatitis, influenza, and emerging infections.
UNAids warns that funding cuts and tightening civic space threaten progress against HIV. Six-month lenacapavir injections are rolling out in South Africa, with early results showing promise but concerns over access and equity persist as external aid declines.
A Bundibugyo Ebola outbreak is driving rapid development of vaccines and antibody therapies. Doses of MBP134 are being used for compassionate use and clinical trials, while several vaccine candidates are advancing toward human testing. Trials face challenges from battlefield-like conditions in eastern Congo and Uganda.
Health authorities have reported at least 1,759 confirmed Ebola cases and about 600 deaths in the Democratic Republic of Congo since mid-May, driven by the rare Bundibugyo strain. The World Health Organization has enrolled the first patient in a trial testing MBP134 and remdesivir; treatment centres are strained and insecurity and funding shortfalls are hindering response.
Frontline workers at Ituri’s Ebola response facilities have struck over unpaid wages as the Bundibugyo outbreak expands to more provinces. The situation adds strain to an already overwhelmed health system, with clinics at capacity and mistrust hampering containment efforts. New cases have been confirmed in Haut-Uele and Tshopo, raising the outbreak’s regional footprint.
Multiple vaccines and therapies are advancing as researchers test protection against Bundibugyo Ebola. Oxford and Serum Institute-led programs are moving into early human trials, while regional bodies prepare for broader studies amid rising case numbers in the Democratic Republic of Congo and neighbouring Uganda.
Companies like Kalshi are expanding prediction markets to biotech trials, linking drug trial outcomes to tradable contracts. Bloomberg and The Guardian report Kalshi’s pilot, its safeguards, and regulatory concerns, as markets push for open data on trial probabilities amid regulatory decisions.